Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Bioorg Med Chem. 2013 Nov 21;22(1):303–310. doi: 10.1016/j.bmc.2013.11.024

Table 2.

Docking of compounds prepared in Schemes 1 and 2 into the agonist and antagonist conformations of ERα and ERβ

Compound Docking score for ERα agonist (kcal mol−1) Docking score for ERα antagonist (kcal mol−1) Docking score for ERβ agonist (kcal mol−1) Docking score for ERβ antagonist (kcal mol−1)
E2 −10.36 −9.70 −10.11 −9.29
4 −10.29 −10.38 −10.66 −10.13
2 −9.82 −9.86 −10.40 −9.71
11 −9.80 −9.30 −10.18 −10.28
7 −9.74 −9.37 −10.00 −10.36
10 −8.82 −9.21 −6.41 −10.08
13 −8.73 −8.82 −4.82 −9.92
18 −8.22 −7.66 −7.86 −7.48
17 −7.37 −7.10 −6.97 −6.83
16 −7.27 −6.99 −6.92 −6.96
20 −6.93 −7.20 −7.34 −7.11
15 −6.85 −6.38 −6.56 −6.77
14 −6.41 −6.28 −6.43 −6.60

Compounds identified as having ERα affinity in the fluorescence polarization displacement assay are in bold.